Inhibitory activities of<i>Ulva lactuca</i>polysaccharides on digestive enzymes related to diabetes and obesity

Belhadj, Sahla; Hentati, Olfa; Elfeki, Abdelfattah; Hamden, Khaled

doi:10.3109/13813455.2013.775159

Cited by 49 publications

(25 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,21 The current studies had few adverse events, all gastrointestinal in nature, and none resulting in discontinuation from the study. Similar to other α-glucosidase inhibitors, the primary complaints of BTI320 were flatulence and abdominal distress, which appeared to be dose dependent.…”

Section: Discussionmentioning

confidence: 74%

See 1 more Smart Citation

Phase 1 Study of the Pharmacology of BTI320 Before High‐Glycemic Meals

Luke

Lee²,

Rausch³

et al. 2018

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

BTI320 is a proprietary fractionated mannan polysaccharide being studied for attenuation of postprandial glucose excursion. The apparent blood glucose-lowering effect of this compound is effective in lowering postprandial hyperinsulinemia, participating in the metabolic regulation of other lipid molecules; the consequence of this activity is yet to be validated with BTI320 with respect to the risk of cardiovascular disease. The primary objective of the study was to determine the postprandial glucose and insulin responses to 3 test meals containing rice alone or consumed with BTI320 (study A) or 3 test meals (Sprite ) alone or consumed with BTI320 (study B). Twenty overweight but otherwise healthy volunteers, 4 female and 6 male (mean age 29 years, BMI 27-28 kg/m ) in study A and 6 female and 4 male (mean age 32 years, BMI 25-32 kg/m ) in study B participated in the BTI320 evaluations. Standardized postprandial response methodology was utilized. In study A the addition of 6- and 12-g BTI320 tablets reduced postprandial glucose responses to white rice by 19% and 32% and reduced postprandial insulin responses by 16% and 24%, respectively (P ≤ .05). In study B 2.6 and 5.2 g BTI320 reduced the glycemic index by 10% and 14%, respectively, and led to 14% and 18% decreases in the insulinemic index of the soft drink (P ≤ .05). These 2 studies demonstrated that the consumption of BTI320 before carbohydrate food or sugary beverage significantly reduced postprandial glucose levels and insulin responses to that meal or beverage in a dose-dependent manner.

show abstract

Section: Discussionmentioning

confidence: 74%

“…Similar to other α-glucosidase inhibitors, the primary complaints of BTI320 were flatulence and abdominal distress, which appeared to be dose dependent. 20,21 The current studies had few adverse events, all gastrointestinal in nature, and none resulting in discontinuation from the study.…”

Section: Discussionmentioning

confidence: 74%

Phase 1 Study of the Pharmacology of BTI320 Before High‐Glycemic Meals

Luke

Lee²,

Rausch³

et al. 2018

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

“…lactuca could significantly decrease the blood glucose by their potential inhibitory effect on key enzymes closely related to starch digestion and absorption in both plasma and small intestine (Belhadj, Hentati, Elfeki, & Hamden, 2013). The Ulva rigida ethanolic extract decreased blood glucose concentrations and micronuclei frequency in diabetic rats (Celikler et al, 2009;Tas, Celikler, Ziyanok-Ayvalik, Sarandol, & Dirican, 2011).…”

Section: Chlorophyta (Green Algae)mentioning

confidence: 99%

“…Activation of both AMPK and Akt signal pathways; Improvement of insulin Ulva lactuca Polysaccharides α-Amylase, maltase and sucrase inhibition; Delay glucose absorption Belhadj et al, 2013…”

Section: Pelvetia Siliquosamentioning

confidence: 99%

Bioactive compounds from marine macroalgae and their hypoglycemic benefits

Zhao

Yang

Liu

et al. 2018

Trends in Food Science & Technology

207

102

View full text Add to dashboard Cite

Bioactive compounds from marine macroalgae and their hypoglycemic benefits http://researchonline.ljmu.ac.uk/id/eprint/7721/ Article LJMU has developed LJMU Research Online for users to access the research output of the University more effectively.Abstract: Diabetes mellitus is a group of chronic metabolic disorders characterized by hyperglycemia due to defects in insulin action and/or secretion. It is a worldwide problem which has led to illness and premature mortality for many people, and the number of diabetes cases has been rising sharply. Unluckily, many conventional antidiabetic agents either show limited efficacy or serious mechanism-based side effects. Marine macroalgae possess tremendous nutritional value and have been well-known to cure and prevent diabetes. An increased interest in various bioactive natural products from marine macroalgae, as a potential source of effective antidiabetic agents, has been observed in recent years. The effects of macroalgae may delay the development of diabetes and alter the metabolic abnormalities through various mechanisms of actions. This review provides an overview of marine macroalgae used to prevent and manage diabetes and explores the hypoglycemic properties of macroalgae-derived bioactive compounds such as polyphenol, bromophenols, sulfated polysaccharides, fucoidan, fucosterol, phlorotannins, carotenoid pigments and fucoxanthin with their probable mechanisms behind hypoglycemic activity. Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent α-glucosidase and α-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice.

show abstract

“…Table 2 reports new drugs and drug derivatives obtained by different marine organisms proposed in anti-obesity treatment [62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94]. …”

Section: Treatment Of Obesitymentioning

confidence: 99%

Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives

et al. 2017

View full text Add to dashboard Cite

Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).

show abstract

Inhibitory activities ofUlva lactucapolysaccharides on digestive enzymes related to diabetes and obesity

Cited by 49 publications

References 32 publications

Phase 1 Study of the Pharmacology of BTI320 Before High‐Glycemic Meals

Phase 1 Study of the Pharmacology of BTI320 Before High‐Glycemic Meals

Bioactive compounds from marine macroalgae and their hypoglycemic benefits

Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives

Contact Info

Product

Resources

About